spacer
home > epc > spring 2017 > risky business
PUBLICATIONS
European Pharmaceutical Contractor

Risky Business

The globalisation of clinical trials and speciality pharmaceutical commercialisation, along with the rise of complex biologicalbased drug therapies, presents a host of opportunities for manufacturers. However, today’s mobile supply chain also comes with substantial risks. If overlooked, it can leave manufacturers, investors and an industry worth approximately $1.1 trillion exposed to potentially significant losses.

Managing the transportation of biopharmaceutical logistics cost almost $79 billion in 2016, with temperature-controlled products accounting for nearly $13 billion, according to Pharmaceutical Commerce’s annual Biopharma Cold Chain Sourcebook. With a growth rate of 8-9% year-on-year, spending on temperature-controlled logistics is predicted to rise to almost $17 billion by 2020, and the non-cold chain is estimated at $77 billion.

Such expense necessitates the identification and qualification of investment to mitigate mounting risks.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Nils Markmann is Vice President of Global Operations at World Courier and is responsible for the daily management of their global operation in terms of networkwide implementation and adherence to global standards, as well as for ensuring consistent operational excellence throughout the company’s 140 offices. Formerly General Manager of Operations for World Courier Germany, Nils has been with the company since 1995.
spacer
Nils Markmann
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aptus Clinical enters into a global partnership agreement with Artelo Biosciences

We are delighted to announce that Aptus Clinical has entered into an agreement with Artelo Biosciences to provide clinical development support the re-purposing of its high-potency dual cannabinoid agonist ART27.13 in oncology.
More info >>

White Papers

Challenges of Analytical Method Transfer in the Pharmaceutical Industry

RSSL

The development and validation of suitable analytical methods is a critical part of the overall drug-development life-cycle. For the majority of products, particularly those that are clinically successful, the transfer of the analytical method between laboratories will be required. This process is designed to verify that a given laboratory is capable of performing a test method for its intended purpose. This can be performed either internally (at the same company), or, with the on-going increasing trend in outsourcing, to an external Contract Research or Development organisation (CRO or CDO).
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement